 Dose finding part: Patients will be recruited to receive combination of defined sorafenib dose 2x400mg with increasing dose of everolimus 2.5mg, 5mg, 7.5mg, 10mg. There will be a run-in phase of 14 days of everolimus followed by combination sorafenibeverolimus starting from day 15. The combination will be continued as long as it is tolerated by the patient and the patient benefits from the treatment according to RECIST criteria. The maximal tolerated dose will be establish in 33 design. Patients will be recruited sequentially at least 14 days apart. The next dose level according to 33 design will be initiated if all patients on the previous dose level reach day 29. 